Acción ARALEZ PHARMACEUTICALS INC
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Aralez Pharmaceuticals Inc Nasdaq

Acciones

CA03852X1006

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Old API Wind-Down Ltd. Announces Management Changes
Aralez Pharmaceuticals Inc. has Changed its Name to Old API Wind-down Ltd
Aralez Pharmaceuticals Inc. Announces Management Changes
Nuvo Pharmaceuticals Inc. completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc..
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Composite Index
Aralez Pharmaceuticals Inc. Announces the Resignation of Seth A. Rudnick, Neal F. Fowler and Rob Harris as Directors
Nuvo Pharmaceuticals Inc. signed a letter of intent to acquire Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. for $62.5 million.
Aralez Pharmaceuticals Inc. Announces Resignation of James Tursi as Chief Medical Officer, Effective from August 2, 2018
Aralez Pharmaceuticals Inc. Enters into an Amendment to that Certain Second Amended and Restated Facility Agreement with Deerfield Partners, L.P
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
Aralez Pharmaceuticals Inc. Announces Resignation of Mark Glickman as Chief Commercial Officer, Effective on March 30, 2018
Aralez Pharmaceuticals Inc. Appoints Michael Kaseta as Chief Financial Officer
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Provides Earnings Guidance for the Fiscal Year 2018
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Biotechnology Index
Aralez Pharmaceuticals Inc. Announces Executive Changes
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Revises Earnings Guidance for the Year Ending December 31, 2017 and provides Preliminary Guidance for Full Year Ending December 31, 2018
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from S&P Global BMI Index
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Revises Earnings Guidance for the Full Year 2017
Aralez Pharmaceuticals Inc. Announces National Commercial Launch of Zontivity in US
Aralez Pharmaceuticals Inc. Announces Resignation of Jason M. Aryeh as Board Member
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ARLZQ
  4. Acción
  5. Noticias Aralez Pharmaceuticals Inc
  6. Otros idiomas